{"product_id":"methods-and-applications-of-statistics-in-clinical-trials-volume-1-and-volume-2-isbn-9781118790786","title":"Methods and Applications of Statistics in Clinical Trials, Volume 1 and Volume 2","description":"\u003cp\u003e\u003cb\u003eThis set includes \u003ci\u003e\u003ca href=\"http:\/\/www.wiley.com\/WileyCDA\/WileyTitle\/productCd-111830473X.html\"\u003eMethods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs\u003c\/a\u003e \u003c\/i\u003e\u0026amp; \u003ci\u003e\u003ca href=\"http:\/\/www.wiley.com\/WileyCDA\/WileyTitle\/productCd-1118304764.html\"\u003eMethods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods\u003c\/a\u003e.\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cbr\u003eVolume 1\u003c\/p\u003e \u003cp\u003e\u003ci\u003eMethods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs\u003c\/i\u003e successfully upholds the goals of the \u003ci\u003eWiley Encyclopedia of Clinical Trials\u003c\/i\u003e by combining both previously-published and newly developed contributions written by over 100 leading academics, researchers, and practitioners in a comprehensive, approachable format. The result is a succinct reference that unveils modern, cutting-edge approaches to acquiring and understanding data throughout the various stages of clinical trial design and analysis.\u003c\/p\u003e \u003cp\u003eVolume 2\u003c\/p\u003e \u003cp\u003eFeaturing newly-written material as well as established literature from the \u003ci\u003eWiley Encyclopedia of Clinical Trials\u003c\/i\u003e, this book provides a timely and authoritative review of techniques for planning clinical trials as well as the necessary inferential methods for analyzing collected data.\u003c\/p\u003e This comprehensive volume features established and newly-written literature on the key statistical principles and concepts for designing modern-day clinical trials, such as hazard ratio, flexible designs, confounding, covariates, missing data, and longitudinal data. Examples of ongoing, cutting-edge clinical trials from today's research such as early cancer \u0026amp; heart disease, mother to child human immunodeficiency virus transmission, women's health initiative dietary, and AIDS clinical trials are also explored. \u003cp\u003e\u003cb\u003eVOLUME 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eContributors xxiii\u003c\/p\u003e \u003cp\u003ePreface xxix\u003c\/p\u003e \u003cp\u003e1 Absolute Risk Reduction 1\u003c\/p\u003e \u003cp\u003e2 Accelerated Approval 14\u003c\/p\u003e \u003cp\u003e3 AIDS Clinical Trials Group (ACTG) 27\u003c\/p\u003e \u003cp\u003e4 Algorithm-Based Designs 40\u003c\/p\u003e \u003cp\u003e5 Alpha-Spending Function 53\u003c\/p\u003e \u003cp\u003e6 Application of New Designs in Phase I Trials 65\u003c\/p\u003e \u003cp\u003e7 ASCOT Trial 74\u003c\/p\u003e \u003cp\u003e8 Benefit\/Risk Assessment in Prevention Trials 80\u003c\/p\u003e \u003cp\u003e9 Biased Coin Randomization 90\u003c\/p\u003e \u003cp\u003e10 Biological Assay, Overview 106\u003c\/p\u003e \u003cp\u003e11 Block Randomization 125\u003c\/p\u003e \u003cp\u003e12 Censored Data 139\u003c\/p\u003e \u003cp\u003e13 Clinical Data Coordination 146\u003c\/p\u003e \u003cp\u003e14 Clinical Data Management 164\u003c\/p\u003e \u003cp\u003e15 Clinical Significance 170\u003c\/p\u003e \u003cp\u003e16 Clinical Trial Misconduct 191\u003c\/p\u003e \u003cp\u003e17 Clinical Trials, Early Cancer and Heart Disease 205\u003c\/p\u003e \u003cp\u003e18 Cluster Randomization 216\u003c\/p\u003e \u003cp\u003e19 Coherence in Phase I Clinical Trials 230\u003c\/p\u003e \u003cp\u003e20 Compliance and Survival Analysis 240\u003c\/p\u003e \u003cp\u003e21 Composite Endpoints in Clinical Trials 246\u003c\/p\u003e \u003cp\u003e22 Confounding 252\u003c\/p\u003e \u003cp\u003e23 Control Groups 263\u003c\/p\u003e \u003cp\u003e24 Coronary Drug Project 273\u003c\/p\u003e \u003cp\u003e25 Covariates 285\u003c\/p\u003e \u003cp\u003e26 Crossover Design 300\u003c\/p\u003e \u003cp\u003e27 Crossover Trials 310\u003c\/p\u003e \u003cp\u003e28 Diagnostic Studies 320\u003c\/p\u003e \u003cp\u003e29 DNA Bank 340\u003c\/p\u003e \u003cp\u003e30 Up-and-Down and Escalation Designs 353\u003c\/p\u003e \u003cp\u003e31 Dose Ranging Crossover Designs 362\u003c\/p\u003e \u003cp\u003e32 Flexible Designs 383\u003c\/p\u003e \u003cp\u003e33 Gene Therapy 399\u003c\/p\u003e \u003cp\u003e34 Global Assessment Variables 423\u003c\/p\u003e \u003cp\u003e35 Good Clinical Practice (GCP) 438\u003c\/p\u003e \u003cp\u003e36 Group-Randomized Trials 448\u003c\/p\u003e \u003cp\u003e37 Group Sequential Designs 467\u003c\/p\u003e \u003cp\u003e38 Hazard Ratio 483\u003c\/p\u003e \u003cp\u003e39 Large Simple Trials 500\u003c\/p\u003e \u003cp\u003e40 Longitudinal Data 510\u003c\/p\u003e \u003cp\u003e41 Maximum Duration and Information Trials 515\u003c\/p\u003e \u003cp\u003e42 Missing Data 522\u003c\/p\u003e \u003cp\u003e43 Mother to Child Human Immunodeficiency Virus Transmission Trials 536\u003c\/p\u003e \u003cp\u003e44 Multiple Testing in Clinical Trials 550\u003c\/p\u003e \u003cp\u003e45 Multicenter Trials 558\u003c\/p\u003e \u003cp\u003e46 Multiple Endpoints 570\u003c\/p\u003e \u003cp\u003e47 Multiple Risk Factor Intervention Trial 577\u003c\/p\u003e \u003cp\u003e48 N-of-1 Randomized Trials 587\u003c\/p\u003e \u003cp\u003e49 Noninferiority Trial 598\u003c\/p\u003e \u003cp\u003e50 Nonrandomized Trials 609\u003c\/p\u003e \u003cp\u003e51 Open-Labeled Trials 619\u003c\/p\u003e \u003cp\u003e52 Optimizing Schedule of Administration in Phase I Clinical Trials 625\u003c\/p\u003e \u003cp\u003e53 Partially Balanced Designs 635\u003c\/p\u003e \u003cp\u003e54 Phase I\/II Clinical Trials 658\u003c\/p\u003e \u003cp\u003e55 Phase II\/III Trials 667\u003c\/p\u003e \u003cp\u003e56 Phase I Trials 682\u003c\/p\u003e \u003cp\u003e57 Phase II Trials 692\u003c\/p\u003e \u003cp\u003e58 Phase III Trials 700\u003c\/p\u003e \u003cp\u003e59 Phase IV Trials 711\u003c\/p\u003e \u003cp\u003e60 Phase I Trials in Oncology 719\u003c\/p\u003e \u003cp\u003e61 Placebos 725\u003c\/p\u003e \u003cp\u003e62 Planning a Group-Randomized Trial 736\u003c\/p\u003e \u003cp\u003e63 Postmenopausal Estrogen\/Progestin Interventions Trial (PEPI) 744\u003c\/p\u003e \u003cp\u003e64 Preference Trials 759\u003c\/p\u003e \u003cp\u003e65 Prevention Trials 770\u003c\/p\u003e \u003cp\u003e66 Primary Efficacy Endpoint 779\u003c\/p\u003e \u003cp\u003e67 Prognostic Variables in Clinical Trials 789\u003c\/p\u003e \u003cp\u003e68 Randomization Procedures 799\u003c\/p\u003e \u003cp\u003e69 Randomization Schedule 813\u003c\/p\u003e \u003cp\u003e70 Repeated Measurements 827\u003c\/p\u003e \u003cp\u003e71 Simple Randomization 841\u003c\/p\u003e \u003cp\u003e72 Subgroups 850\u003c\/p\u003e \u003cp\u003e73 Superiority Trials 867\u003c\/p\u003e \u003cp\u003e74 Surrogate Endpoints 878\u003c\/p\u003e \u003cp\u003e75 TNT Trial 887\u003c\/p\u003e \u003cp\u003e76 UGDP Trial 894\u003c\/p\u003e \u003cp\u003e77 Women's Health Initiative Hormone Therapy Trials 918\u003c\/p\u003e \u003cp\u003e78 Women's Health Initiative Dietary Modification Trial 931\u003c\/p\u003e \u003cp\u003eIndex 945\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 2\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eContributors xix\u003c\/p\u003e \u003cp\u003ePreface xxiii\u003c\/p\u003e \u003cp\u003e1 Analysis of Over- and Underdispersed Data 1\u003c\/p\u003e \u003cp\u003e2 Analysis of Variance (ANOVA) 10\u003c\/p\u003e \u003cp\u003e3 Assessment of Health-Related Quality of Life 26\u003c\/p\u003e \u003cp\u003e4 Bandit Processes and Response-Adaptive Clinical Trials: The Art of Exploration Versus Exploitation 40\u003c\/p\u003e \u003cp\u003e5 Bayesian Dose-Finding Designs in Healthy Volunteers 51\u003c\/p\u003e \u003cp\u003e6 Bootstrap 62\u003c\/p\u003e \u003cp\u003e7 Conditional Power in Clinical Trial Monitoring 102\u003c\/p\u003e \u003cp\u003e8 Cost-Effectiveness Analysis 111\u003c\/p\u003e \u003cp\u003e9 Cox-Type Proportional Hazards Models 126\u003c\/p\u003e \u003cp\u003e10 Empirical Likelihood Methods in Clinical Experiments 146\u003c\/p\u003e \u003cp\u003e11 Frailty Models 166\u003c\/p\u003e \u003cp\u003e12 Futility Analysis 174\u003c\/p\u003e \u003cp\u003e13 Imaging Science in Medicine I: Overview 187\u003c\/p\u003e \u003cp\u003e14 Imaging Science in Medicine, II: Basics of X-Ray Imaging 213\u003c\/p\u003e \u003cp\u003e15 Imaging Science in Medicine, III: Digital (21st Century) X-Ray Imaging 264\u003c\/p\u003e \u003cp\u003e16 Intention-to-Treat Analysis 313\u003c\/p\u003e \u003cp\u003e17 Interim Analyses 323\u003c\/p\u003e \u003cp\u003e18 Interrater Reliability 334\u003c\/p\u003e \u003cp\u003e19 Intrarater Reliability 340\u003c\/p\u003e \u003cp\u003e20 Kaplan-Meier Plot 357\u003c\/p\u003e \u003cp\u003e21 Logistic Regression 365\u003c\/p\u003e \u003cp\u003e22 Metadata 380\u003c\/p\u003e \u003cp\u003e23 Microarray 392\u003c\/p\u003e \u003cp\u003e24 Multi-Armed Bandits, Gittins Index, and Its Calculation 416\u003c\/p\u003e \u003cp\u003e25 Multiple Comparisons 436\u003c\/p\u003e \u003cp\u003e26 Multiple Evaluators 446\u003c\/p\u003e \u003cp\u003e27 Noncompartmental Analysis 457\u003c\/p\u003e \u003cp\u003e28 Nonparametric ROC Analysis for Diagnostic Trials 483\u003c\/p\u003e \u003cp\u003e29 Optimal Biological Dose for Molecularly Targeted Therapies 496\u003c\/p\u003e \u003cp\u003e30 Over- and Underdispersion Models 506\u003c\/p\u003e \u003cp\u003e31 Permutation Tests in Clinical Trials 527\u003c\/p\u003e \u003cp\u003e32 Pharmacoepidemiology, Overview 536\u003c\/p\u003e \u003cp\u003e33 Population Pharmacokinetic and Pharmacodynamic Methods 551\u003c\/p\u003e \u003cp\u003e34 Proportions: Inferences and Comparisons 570\u003c\/p\u003e \u003cp\u003e35 Publication Bias 595\u003c\/p\u003e \u003cp\u003e36 Quality of Life 608\u003c\/p\u003e \u003cp\u003e37 Relative Risk Modeing 622\u003c\/p\u003e \u003cp\u003e38 Sample Size Considerations for Morbidity\/Mortality Trials 633\u003c\/p\u003e \u003cp\u003e39 Sample Size for Comparing Means 642\u003c\/p\u003e \u003cp\u003e40 Sample Size for Comparing Proportions 653\u003c\/p\u003e \u003cp\u003e41 Sample Size for Comparing Time-to-Event Data 664\u003c\/p\u003e \u003cp\u003e42 Sample Size for Comparing Variabilities 672\u003c\/p\u003e \u003cp\u003e43 Screening, Models of 689\u003c\/p\u003e \u003cp\u003e44 Screening Trials 721\u003c\/p\u003e \u003cp\u003e45 Secondary Efficacy End Points 731\u003c\/p\u003e \u003cp\u003e46 Sensitivity, Specificity, and Receiver Operator Characteristic (ROC) Methods 740\u003c\/p\u003e \u003cp\u003e47 Software for Genetics\/Genomics 752\u003c\/p\u003e \u003cp\u003e48 Stability Study Designs 778\u003c\/p\u003e \u003cp\u003e49 Subgroup Analysis 793\u003c\/p\u003e \u003cp\u003e50 Survival Analysis, Overview 802\u003c\/p\u003e \u003cp\u003e51 The FDA and Regulatory Issues 815\u003c\/p\u003e \u003cp\u003e52 The Kappa Index 836\u003c\/p\u003e \u003cp\u003e53 Treatment Interruption 846\u003c\/p\u003e \u003cp\u003e54 Trial Reports: Improving Reporting, Minimizing Bias, and Producing Better Evidence-Based Practice 860\u003c\/p\u003e \u003cp\u003e55 U.S. Department of Veterans Affairs Cooperative Studies Program 876\u003c\/p\u003e \u003cp\u003e56 Women's Health Initiative: Statistical Aspects and Selected Early Results 901\u003c\/p\u003e \u003cp\u003e57 World Health Organization (WHO): Global Health Situation 914\u003c\/p\u003e \u003cp\u003eIndex 925\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eN. BALAKRISHNAN\u003c\/strong\u003e is Professor in the Department of Mathematics and Statistics at McMaster University, Canada. He is a Fellow of the American Statistical Association. His publications include other Wiley books: A First Course in Order Statistics, Continuous Univariate Distributions - 1 \u0026amp; 2, and Discrete Multivariate Distributions.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989615132901,"sku":"NP9781118790786","price":406.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118790786.jpg?v=1761784818","url":"https:\/\/k12savings.com\/es\/products\/methods-and-applications-of-statistics-in-clinical-trials-volume-1-and-volume-2-isbn-9781118790786","provider":"K12savings","version":"1.0","type":"link"}